Endometrial hyperplasia screening

Endometrial hyperplasia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Endometrial hyperplasia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Case Studies
Case #1
Endometrial hyperplasia screening On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Endometrial hyperplasia screening All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Endometrial hyperplasia screening
CDC on Endometrial hyperplasia screening
Endometrial hyperplasia screening in the news
Blogs on Endometrial hyperplasia screening
Directions to Hospitals Treating Endometrial hyperplasia
Risk calculators and risk factors for Endometrial hyperplasia screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Swathi Venkatesan, M.B.B.S.[2]

Oveview

Routine screening for endometrial hyperplasia or endometrial carcinoma is not recommended.

Screening

• Women receiving unopposed estrogens should undergo endometrial sampling once every 2 years.
• Particularly if endometrial hyperstimulation was documented previously and is not been treated by short-term progestins.
• If high-risk individual requests an endometrial evaluation before or during HRT.
• Women at high risk for endometrial carcinoma, such as history of Lynch II syndrome.